Anthem Biosciences IPO: All you need to know

Particulars	Details
IPO Open Date	July 14, 2025
IPO Close Date	July 16, 2025
Price Band	₹540 to ₹570 per share
Lot Size	26 Shares
Issue Size	5,95,61,404 shares (₹3,395.00 Cr)
Listing At	BSE, NSE
Tentative Listing Date	To be announced

The global pharmaceutical industry is projected to grow to USD 2,076.0 billion by 2029, driven by innovation, rising healthcare demands, and expanding R&D activity. Within this landscape, CROs and CDMOs are increasingly integrating their services to offer end-to-end CRDMO solutions, becoming strategic partners for pharma and biotech companies. India is rapidly emerging as a global hub in this space, with the domestic CRDMO industry expected to grow at a CAGR of 13.4% between 2024 and 2029, reaching USD 15.4 billion, outpacing the global growth rate of 9.1%. Despite sector-wide challenges like rising costs, regulatory tightening, and low experimental success rates, India’s strong technical capabilities and cost-efficient base position it favorably to capture higher market share in the global pharma outsourcing ecosystem.

Anthem Biosciences Ltd is an innovation driven and technology focused Contract Research, Development, and Manufacturing Organization (CRDMO) with fully integrated operations spanning drug discovery, development, and commercial manufacturing. The company is among the few Indian players offering both New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across the pharma value chain. Its CRDMO platform is built around five key modalities – RNAi, ADC, peptides, lipids, and oligonucleotides and four core manufacturing technologies, namely custom synthesis, flow chemistry, fermentation, and biotransformation. Anthem serves a global client base of emerging biotech innovators and large pharmaceutical companies, deriving the majority of its revenue from CRDMO services, including research & development, developmental and commercial manufacturing, along with supplementary revenue from its specialty ingredients division.

Anthem Biosciences has delivered a strong financial performance, with revenue from operations growing to ₹18,445.5 million in FY25, reflecting a robust CAGR of over 31% from FY23. This growth continues to be led by its CRDMO segment, which contributed over 80% of total revenues in FY25. EBITDA for the year rose 31.5% YoY to ₹6,837.8 million, with margins sustaining at a healthy 36.8%. Profit after tax (PAT) increased by 22.9% YoY to ₹4,512.6 million, supported by operating leverage and scale. Diluted EPS improved steadily to ₹8.04 in FY25, up from ₹6.48 in FY24, reflecting consistent profitability growth. Furthermore, the company significantly reduced its borrowings to ₹1,089.5 million in FY25 from ₹2,325.3 million in FY24, strengthening its balance sheet and improving financial flexibility.

Objects of the issue: 

1. Offer for sale – INR 33,950 million

📱 Apply Online through the SMIFS ELITE App | Download now:

Experience seamless investing at your fingertips!